Company Overview and News

66
7 Self-Driving Car Stocks Veering Off the Road

2018-09-14 investorplace
When the concept first materialized, autonomous vehicles were strictly limited to science fiction. As technology shifted from merely processing data into independently analyzing it, the driverless industry became science fact. Naturally, investment analysts pushed self-driving car stocks as the next big thing.
AVX VC MGA ADNT TSLA GM APTV

2
ADNT / Adient plc FORM 8-K (Current Report)

2018-09-13 sec.gov - 2
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ADNT

111
Tracking David Einhorn's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 7
Greenlight's long/short ratio is at 96% long and 75% short compared to 111% long and 82% short last quarter.
TWX AZO MET BLMN DLTR TJX CEIX.WI SFM DSW CLPPZ AABA TWTR VNTR CLPR GLRE CNX.WI ADNT TWC XRX CNDT BHF ROKU GPS ATHN GRBK CCR MDCO NFLX PYPL HUN VOYA ESV ODP AAPL GM CEIX DDS XELA TPR TPX MU DG PRGO TSLA URBN FIVE CNX

 
Adient (ADNT) Benefits From Stabilization of SS&M Segment

2018-08-15 zacks
We issued an updated research report on Adient plc (ADNT - Free Report) on Aug 14. Dublin, Ireland-based Adient plc is a leading global automotive seating supplier. It designs, manufactures, and markets a full range of seating systems and components for passenger cars, commercial vehicles and light trucks — including vans, pick-up trucks and sport/crossover utility vehicles. The company operates around 238 wholly- and majority-owned manufacturing or assembly facilities, with operations in 34 countries.
CVGI ADNT MTOR ALSN

 
Adient PLC: Okay, What Just Happened Here?

2018-07-31 seekingalpha
Centaur Investments continues to maintain a $40 price target and avoid opinion on the company's shares.
ADNT

 
ADNT / Adient plc 10-Q (Quarterly Report)

2018-07-30 sec.gov
Document UNITED STATES
ADNT

2
Adient's (ADNT) Q3 Earnings Miss Estimates, Revenues Up

2018-07-27 zacks
Adient plc (ADNT - Free Report) reported third-quarter fiscal 2018 earnings per share of $1.45, lagging the Zacks Consensus Estimate of $1.56. The bottom-line figure in the year-ago quarter was $2.49 per share. During the quarter under review, the company reported net sales of $4.5 billion, up 12% from that of third-quarter fiscal 2017. Also, the top line beat the Zacks Consensus Estimate of $4.3 billion.
FOXF EA OSK ADNT NVR TRN

 
ADNT / Adient plc FORM 8-K (Current Report)

2018-07-27 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ADNT

 
Adient plc 2018 Q3 - Results - Earnings Call Slides

2018-07-26 seekingalpha
The following slide deck was published by Adient plc in conjunction with their 2018 Q3 earnings call.
ADNT

 
ADNT / Adient plc 8-K (Current Report)

2018-07-26 sec.gov
Document
ADNT

5
New Strong Sell Stocks for July 16th

2018-07-16 zacks
Adient plc (ADNT - Free Report) is a designer of a range of seating systems and components. The Zacks Consensus Estimate for its current year earnings has been revised 3.7% downward over the last 30 days.
BUD GTT ADNT HZN AHBIF

44
Oakmark Select Fund: Second Quarter 2018

2018-07-11 seekingalpha
For the quarter, the Oakmark Select Fund declined 0.4%, compared to a 3.4% increase in the S&P 500 Index, the Fund’s benchmark. Year to date, the Fund declined 4.3%, compared to a 2.7% increase for the S&P 500.
MGM REGN CKRGZ APA AAL ADNT CHKVP HOG CHKDH CHKVZ CHKDG CHKWZ CHKDJ CHKDP CHK CHK.WI WFT

 
ADNT / Adient plc FORM 8-K (Current Report)

2018-07-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
ADNT

 
ADNT / Adient plc / DAVIS SELECTED ADVISERS - DAVIS SELECTED ADVISERS (Passive Investment)

2018-07-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* Adient PLC -------------------------------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------------------------------- (Title of Class of Securities) G0084W101 --------------------
ADNT

 
ADNT / Adient plc / DAVIS SELECTED ADVISERS - DAVIS SELECTED ADVISERS (Passive Investment)

2018-07-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* Adient PLC -------------------------------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------------------------------- (Title of Class of Securities) G0084W101 --------------------
ADNT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: G0084W101